Objectives: We evaluated the susceptibility to fusidic acid, mupirocin and retapamulin of Staphylococcus aureus isolated from nasal and wound swabs.
Introduction
Fusidic acid (Leo Pharma) is used topically in Europe, including The Netherlands, to treat skin or soft tissue infections (SSTIs), including impetigo. 1 The increased prevalence of fusidic acidresistant Staphylococcus aureus over time is due to mutations in fusA or the acquisition of the fusB gene. 2 The fusB gene plays a role in the low level of resistance to fusidic acid occurring in the so-called epidemic European fusidic acid-resistant impetigo clone (EEFIC). The clone is further characterized by the presence of exfoliative toxin A (etaA) and often etaB. It belongs to the agr allelic group IV, spa type 171 (or single-repeat variants t408, t659, t874 and t875) and sequence type (ST) 123 [clonal complex (CC) 121]. 2 In 2007, retapamulin (GSK) became available for the topical treatment of impetigo. It belongs to the pleuromutilin class of antibiotics, which inhibit protein synthesis. 3 Retapamulin was as effective as fusidic acid for the treatment of impetigo, but showed slightly more minor drug-related adverse events, such as induction of hypersensitivity. 4 Although approved in Europe, the use of retapamulin in The Netherlands is still limited, possibly due to the lack of refund by the health insurances and its lack of mention in the guidelines of the Dutch General Practitioners (NHG). 5 As no comparative susceptibility data were available, we evaluated the susceptibility of nasal and wound isolates of S. aureus to fusidic acid, mupirocin and retapamulin.
Materials and methods

Study population
From January 2007 to December 2008, general practitioners (GPs) in the south of The Netherlands were asked to include all patients with an SSTI in which S. aureus was suspected. After informed consent had been obtained, swabs from nostril and skin lesions were taken and a questionnaire requesting information about baseline characteristics and diagnosis was filled in by the GP. 5 Swabs and questionnaires were sent to the medical microbiology department of Maastricht University Medical Center (MUMC). The swabs were processed using standard microbiological procedures including real-time PCR for the presence of the mecA gene. 6 Susceptibility to retapamulin (0.03-32 mg/L) and fusidic acid (0.5-1024 mg/L) was determined using a microbroth dilution method, and susceptibility to mupirocin (10 mg) was determined using a disc The study was approved by the Ethics Committee of the MUMC.
Genotype determination
The genetic background of all S. aureus was determined using spa typing. The fusidic acid-resistant isolates were characterized using PFGE and compared with the EEFIC strain CS6. The presence of fusB, fusC and fusD was tested by real-time PCR (MyiQ Single-Color Real-Time PCR Detection System, Bio-Rad Laboratories, Veenendaal, The Netherlands).
The nucleotide sequences were analysed using Chromas (software program) and compared with sequences available through BLAST (http:// www.ncbi.nlm.nih.gov/blast). 6 The characteristics of a fusidic acidsusceptible and -resistant strain with spa type t171 were compared with those of the EEFIC clone with regard to the presence of the agr type and exfoliating toxins, using the S. aureus microarray (Clondiag). 7 
Statistical analysis
Logistic regression analyses were used to examine whether carriage of a fusidic acid-resistant isolate differed between the different age groups. Statistical analyses were performed using SPSS v. 16.0 software (SPSS Inc., Chicago, IL, USA).
Results
Study population
In 110 of the 234 participating patients, S. aureus was found in the nose (47%) and in 133 (57%) in the wound. Twenty-six (11%) of the patients were only nasal carriers and 50 (21%) only had S. aureus in the wound. In 85 patients (36%) S. aureus was present in the nose and the wound. In 30 of these patients the S. aureus strains in the nose differed from those in the wound based on the MIC for fusidic acid, retapamulin or mupirocin, spa type and/or associated multilocus sequence type (MLST) CC. No differences in baseline characteristics were found between patients with or without S. aureus in nose and/or wound (Table 1) . Three patients had a methicillin-resistant S. aureus (MRSA) in the wound; one of them was also a nasal carrier of MRSA (both spa type t002). The others were spa type t477 and t005.
Fusidic acid resistance
Fusidic acid resistance was observed among 25 (23%) nasal and 48 (35%) wound isolates. The four MRSA isolates were fusidic acid susceptible. Of the patients with a fusidic acid-resistant strain, 41% were diagnosed with impetigo and most were younger than 20 years. Patients with a fusidic acid-resistant or Rijnders et al.
-susceptible strain did not differ in baseline characteristics except age (Table 1) .
Genetic determination of fusidic acid resistance
Acquired fusidic acid resistance was present in 92% of the isolates. fusB had the highest prevalence, being present in 81% and 88% of the nasal and wound isolates, respectively. fusC was observed in four isolates and fusD was not detected. Six isolates (two nasal and four wound isolates) were negative for fusB, C, D and E and positive for fusA, and three of them had an MIC .8 mg/L. The fusB gene was present in 65 of the 72 (90%) resistant isolates (MIC ≥2 mg/L) and one susceptible isolate (MIC 1 mg/L). The most common spa types of the fusB-positive isolates were t171 (58%) followed by t659 (15%), t408 (8%), t1636 (8%), t084 (3%), t015, t216, t363 and t2382 (2% each). Four of the isolates with an MIC of 2 mg/L were fusC positive and belonged to spa types t008 and t012. The fusidic acid-resistant isolates from the nose were less heterogeneous in terms of spa types than those from wounds ( Figure 1 ). The spa types t159, t171, t216, t408, t659 and t1636 were associated with a comparable spa CC and had a PFGE pattern comparable to that of the EEFIC clone.
Differences in spa types between fusidic acid-resistant and -susceptible isolates (Figure 1a ) and between the different age groups were observed (Figure 1b) .
In vitro activity of retapamulin and mupirocin
Resistance to mupirocin was found in two methicillin-susceptible S. aureus isolates from nose and wound swabs. The retapamulinresistant strain, a nasal isolate with an MIC of 8 mg/L, was further characterized using an S. aureus microarray and was vgb positive.
Discussion
We investigated fusidic acid resistance in S. aureus isolates from nasal and wound swabs of GP patients with complaints of an SSTI, in comparison with retapamulin and mupirocin. Fusidic acid resistance was found in 23% of nasal and 35% of wound isolates, 77% of which were from patients younger than 20 years. Most of these resistant strains were fusB positive, belonged to spa type t171 or a related spa type and were comparable to the EEFIC clone. Fusidic acid-resistant strains with spa type t008 or t012 were fusC positive. fusD or fusE mutants were not observed. Only one nasal isolate was resistant to retapamulin and two were resistant to mupirocin.
S. aureus nasal carriage was found in 36% of the patients with an SSTI and 65% of them had an infection with the same colonizing strain. The prevalence of S. aureus carriage was higher than the 23% we found in general practice patients without a skin infection. This applied for both methicillin-susceptible S. aureus and MRSA.
The increased prevalence and spread of the EEFIC clone in the south of The Netherlands were in contrast to the decreased prevalence described by Castanheira et al. 8 The difference might be due to: (i) the source of the isolates (i.e. isolates from skin infections of GP patients only in our study versus all infections from hospitalized patients); (ii) the increase in the use of topical fusidic acid in The Netherlands until 2004 to 0.46 DDD/1000 inhabitants/year (where DDD stands for defined daily dose), which remained constant thereafter, whereas systemic use remained low, in contrast with other European countries with a higher systemic use; and (iii) overrepresentation of younger patients because of the higher prevalence of impetigo among this age group. The EEFIC clone was especially observed in this group of patients. The significant differences in carriage of fusidic acid-resistant isolates among children compared with adults suggest that children are more prone to carrying these resistant isolates.
The increasing prevalence of fusidic acid-resistant isolates from wound infections is of concern because the drug is still the empirical choice in cases of impetigo in The Netherlands. 5 Possible alternatives are either mupirocin or retapamulin. As mupirocin is used for decolonization of patients with MRSA, it is not advised for empirical treatment of impetigo. The in vivo study of Oranje et al. 4 confirmed the effectiveness of retapamulin, but side effects and cross-resistance with quinupristin/dlfopristin have been described. 9 Although our study was performed only in the south of The Netherlands, a similar survey in the north also showed that 24% of the isolates were resistant to fusidic acid. 10 In conclusion, the EEFIC clone conferring fusidic acid resistance was relatively highly prevalent among GP patients in the south of The Netherlands. Further studies concerning the usefulness of retapamulin for the empirical treatment of impetigo are warranted.
